Zobrazeno 1 - 10
of 28
pro vyhledávání: ''
Publikováno v:
BMC Cancer
BMC CANCER(13)
BMC CANCER(13)
Background Heregulin (HRG; also known as neuregulin) is a ligand for ErbB3. One of its isotypes, HRG-β1, binds to ErbB3 and forms heterodimers with other ErbB family members, thereby enhancing the proliferation and tumorigenesis of breast cancer cel
Autor:
Sandra Salvi, Pier Vitale Nuzzo, L. Zinoli, Francesco Boccardo, Simona Boccardo, Alessandra Rubagotti
Publikováno v:
BMC Cancer
Background PN is a secreted cell adhesion protein critical for carcinogenesis. In breast cancer, it is overexpressed compared to normal breast, and a few reports suggest that it has a potential role as a prognostic marker. Methods Tumour samples obta
The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer
Autor:
Tibor Krenács, Zsuzsanna Varga, Cosima Riemenschnitter, Janina Kulka, Cornelia Leo, Barna Wichmann, Ivett Teleki, Holger Moch, Marcell A Szász, Bärbel Papassotiropoulos
Publikováno v:
BMC Cancer, Vol 13, Iss 1, p 50 (2013)
BMC Cancer
BMC Cancer
Background Several classification systems are available to assess pathological response to neoadjuvant chemotherapy in breast cancer, but reliable biomarkers to predict the efficiency of primary systemic therapy (PST) are still missing. Deregulation
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 380 (2012)
BMC Cancer
BMC Cancer
Background Tumor development is known to be a stepwise process involving dynamic changes that affect cellular integrity and cellular behavior. This complex interaction between genomic organization and gene, as well as protein expression is not yet fu
Publikováno v:
BMC Cancer. 15(1)
The Adenomatous Polyposis Coli (APC) tumor suppressor is mutated or hypermethylated in up to 70 % of sporadic breast cancers depending on subtype; however, the effects of APC mutation on tumorigenic properties remain unexplored. Using the Apc Min/+ m
Autor:
Hugo M. Horlings, Meaghan Dendy, Tao Su, Lao H. Saal, Neal Rosen, Matthew Maurer, Ramon Parsons, Lorenzo Memeo, Qing-Bai She, Mervi Jumppanen, Jorma Isola, Ying Ka Ingar Lau, Sofia K. Gruvberger-Saal, Marc J. van de Vijver, Yilun Chen, Hanina Hibshoosh
Publikováno v:
BMC cancer, 16(1). BioMed Central
BMC Cancer
BMC Cancer
The basal-like breast cancer (BLBC) subtype is characterized by positive staining for basal mammary epithelial cytokeratin markers, lack of hormone receptor and HER2 expression, and poor prognosis with currently no approved molecularly-targeted thera
Autor:
Debabrata Mukhopadhyay, Asha S. Nair, Priya Srinivas, Sreelatha K. Hemalatha, Krishnendu Pal, Veena Somasundaram, Sutapa Sinha
Publikováno v:
BMC Cancer
Background Studies over the past decade and half have identified cancer stem cells (CSCs) to be responsible for tumorigenesis, invasion, sustenance of metastatic disease, radio- and chemo-resistance and tumor relapse. Recent reports have described th
Publikováno v:
BMC Cancer, Vol 11, Iss 1, p 490 (2011)
BMC Cancer
BMC Cancer
Background Cowden Syndrome (CS) patients with germ line point mutations in the PTEN gene are at high risk for developing breast cancer. It is believed that cells harboring these mutant PTEN alleles are predisposed to malignant conversion. This articl
Autor:
Brittany Singleton, Shawn D. Llopis, Tamika Duplessis, Brian G. Rowan, Christopher Williams, Latonya Carrier
Publikováno v:
BMC Cancer
Background NR4A orphan nuclear receptors are involved in multiple biological processes which are important in tumorigenesis such as cell proliferation, apoptosis, differentiation, and glucose utilization. The significance of NR4A family member NURR1
Autor:
Sang Min Jung, Jin Woo Kim, Hyun Kee Kim, Seon-Ah Ha, Yu Sun Lee, Sang Seol Jung, Hae Joo Kim, Youn Soo Lee, Yeun-Jun Chung, Seung Min Shin, Sanghee Kim, Hong Namkoong
Publikováno v:
BMC Cancer, Vol 9, Iss 1, p 51 (2009)
BMC Cancer
BMC Cancer
Background Oncoprotein HCCR-1 functions as a negative regulator of the p53 and contributes breast tumorigenesis. The serum HCCR-1 assay is useful in diagnosing breast cancer and mice transgenic for HCCR developed breast cancers. But it is unknown how